$0.38
-0.03 (-8.49%)
Open$0.40
Previous Close$0.41
Day High$0.44
Day Low$0.37
52W High$3.01
52W Low$0.24
Volume—
Avg Volume918.1K
Market Cap16.32M
P/E Ratio—
EPS$-0.25
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+3,918.1% upside
Current
$0.38
$0.38
Target
$15.08
$15.08
$11.92
$15.08 avg
$19.61
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 18.42M | 17.19M | 14.45M |
| Net Income | 959.9K | 1.03M | 875.1K |
| Profit Margin | 5.2% | 6.0% | 6.1% |
| EBITDA | 1.74M | 1.49M | 1.43M |
| Free Cash Flow | 993.5K | 1.08M | 606.8K |
| Rev Growth | +1.0% | +13.6% | +14.7% |
| Debt/Equity | 0.15 | 0.16 | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |